|
Documents can be downloade from the DFID Website.
1. Asmal H. Prevalence of anaemia in women screening for participation in a microbicide trial and the follow-up: a public health benefit In: Microbicides 2008. Delhi; 2008.
2. Asmal H. NMB - common adverse effect among women on injectible contraceptives: experiences from mdp 301 In: Microbicides 2008. Delhi; 2008.
3. Asmal H. Reasons for lack of contraceptive use amongst women screening for a microbicide trial and strategies to improve uptake In: Microbicides 2008. Delhi; 2008.
4. Asmal H. Reasons for lack of contraceptive use amongst women screening for a microbicide trial and strategies to improve uptake. In: Microbicides 2008. New Delhi, India; 2008.
5. Asmal H. Nmb – common adverse effect among women on injectible contraceptives: experiences from mdp 301. In: Microbicides 2008. New Delhi, India; 2008.
6. Basajja V. Strategies to recruit and retain couples in a vaginal microbicides trial of pro2000/5 in a rural community, sw uganda In: Microbicides 2008. Delhi; 2008.
7. Buthelezi S. Giving trial participants a voice! Experiences from the mdp301 clinical trial site in the umkhanyakude district of northern kwazulu natal. In: Microbicides 2008. Delhi; 2008.
8. Cairns J. Evaluation of a dual HIV rapid testing strategy for screening into the MDP301 trial. In: Microbicides 2008. Delhi; 2008.
9. Cheelo M. Community mobilization using participant peer educators in mdp 301 clinical trial in mazabuka-zambia In: Microbicides 2008. Delhi; 2008.
10. Concilia J. Strategies used to refocus recruitment efforts to higher risk subgroups during a vaginal microbicide study in, Mwanza Tanzania In: Microbicides 2008. New Delhi, India; 2008.
11. Crook AM. Assessing the reliability of self reported gel use compared to used applicator returns in the ongoing mdp 301 phase iii trial In: Microbicides 2008. Delhi; 2008.
12. Dhookie J. Participant adherence to gel use instructions regarding timing for gel insertion and for vaginal cleansing in the mdp 301 microbicides trial in johannesburg In: Microbicides 2008. Delhi; 2008.
13. Dhookie J. An assessment of the acceptability of a pro 2000/5 microbicide gel in the mdp 301 trial in johannesburg In: Microbicides 2008. Delhi; 2008.
14. Gafos MJ. Encouraging men to initiate discussion about microbicide trial participation with their partners. Experiences of a football tournament hosted by the mdp301 clinical trial in the umkhanyakude district of northern kwazulu natal. In: Microbicides 2008. Delhi; 2008.
15. Gafos MJ. A preference for hot sex! Similarity of descriptors used to explain local vaginal products and vaginal investigational products in the mdp301 clinical trial in the umkhanyakude district of northern kwazulu natal. In: Microbicides 2008. Delhi; 2008.
16. Gafos M, Mzimela M, Sukazi S. The use of intravaginal insertions for the treatment of Sexually Transmitted Infections (STIs) in the Umkhanyakude District of northern KwaZulu Natal. In: XVIIth International AIDS Conference. Mexico; 2008.
17. Gilbert CJ. Is self reported sexual behaviour at the last sex act a good indicator of behaviour at all recent sex acts? . In: Microbicides 2008. Delhi; 2008.
18. Govender S. Can higher retention be achieved in mdp301 than implied by the preceding cohort studies? . In: Microbicides 2008. Delhi; 2008.
19. Kalumbilo SN. Issues affecting understanding of key informed consent messages in the mdp 301 trial in mazabuk,zambia In: Microbicides 2008. Delhi; 2008.
20. Kasse MJ. Recruitment and retention in a vaginal microbicide efficacy trial: experiences with hiv negative women living in discordant couple relationships in rural sw uganda In: Microbicides 2008. Delhi; 2008.
21. Kawuma R. Role of men in a phase iii vaginal microbicide trial in sw uganda In: Microbicides 2008. Delhi; 2008.
22. Kayombo L. Reasons behind low responses to joining the MDP trial by women living in the Sugar Plantation in Mazabuka, Zambia. In: Microbicides 2008. Dehli; 2008.
23. Khoza LG. Challenges with recruiting male partners of participants for acceptability research in hiv prevention trials in south africa. In: Microbicides 2008. New Delhi, India; 2008.
24. Lacey C. Unacceptable side effects of a hyperosmolar vaginal microbicide in a phase 1 trial In: Microbicides 2008. Delhi; 2008.
25. Lees S, Agnes S, Tilki S, et al. Perceptions of the MDP Microbicides Clinical Trial in Mwanza, Tanzania and Masaka, Uganda: Views of participants and people from the wider community (Abs 319). In: Microbicides 2008. Delhi; 2008.
26. Lees S, Hilali E, Matari S, et al. Participants’ reactions to the closure of the 2% PRO2000/5 gel arm of the Microbicides Development Programme (MDP) Phase III Clinical trial: Findings from ethnographic research In: ICASA 2008. Dakar; 2008.
27. Lees S, Barberousse C, Vallely A, et al. Referrals to HIV care and treatment services by women screened for the Microbicides Development Programme Phase III clinical trial of a vaginal microbicide trial in Mwanza, Tanzania: Understanding the barriers to attending the service. In: ICASA 2008. Dakar; 2008.
28. Luwugge HS. Adherence to gel and condom use among women participants in a phase iii microbicide trial of pro2000/ 5 in rural sw uganda In: Microbicides 2008. Delhi; 2008.
29. Maloo J, Shagi C, John C, et al. Strategies used to refocus recruitment efforts to higher risk sub groups during a vaginal microbicide study in Mwanza, Tanzania. In: Microbicides 2008. Delhi 2008.
30. Masanja J, Philemon D, Njeleja S, Moffat C, Hayes R. Use of mobile clinics to conduct a clinical trial among recreational facility workers. In: ICASA 2008. Dakar; 2008.
31. Masuku P. Community information dissemination in a microbicide efficacy trial in johannesburg, south africa In: Microbicides 2008. Delhi; 2008.
32. Mathur R. Genital signs in women with and without laboratory confirmed stis in mdp301 In: Microbicides 2008. Delhi; 2008.
33. Mngadi PT. Sexually transmitted infections (stis) among women enrolled in a microbicide development program (mdp) clinical trial at durban sites In: Microbicides 2008. New delhi; 2008.
34. Mntambo AQ. Patterns of concurrent condom and microbicide use in the mdp 301 trial, johannesburg In: Microbicides 2008. Delhi; 2008.
35. Moffat C, Barberousse C, Mgina E, et al. STI Abstract. In: ICASA 2008. Dakar; 2008.
36. Moffat C. Are previous enrollees in a feasibility study a suitable study population from which to recruit for an HIV prevention trial. In: Microbicides 2008. New Delhi, India; 2008.
37. Montgomery CM. Pleasure and prevention: african women's voices on microbicide gel use In: Microbicides 2008. Delhi; 2008.
38. Montgomery CM. Capturing heterosexual anal sex in a phase iii vaginal microbicide trial: using qualitative methods to understand community norms In: Microbicides 2008. Delhi; 2008.
39. Montgomery CM. Emic perspectives on microbicides and sexual health: a new approach to acceptability In: Microbicides 2008. Delhi 2008.
40. Mshibe LC. Impact of myths and misconceptions of contraceptive practices in mdp participants, durban. . In: Microbicides 2008. Delhi; 2008.
41. Musonda MC, Mweemba O, Chisembele M, Siziya S, Montgomery C, Pool R. Vaginal cleaning practices among women in mdp microbicide trial in mazabuka, zambia In: Microbicides 2008. Delhi; 2008.
42. Mutevedzi PC. Burden and determinants of bacterial vaginosis in hiv uninfected women aged 18 years and over, enrolled in the mdp301 clinical trial in the umkhanyakude district of northern kwazulu natal. In: Microbicides 2008. Delhi; 2008.
43. Mweemba O. Partner involvement in gel use: the case of mdp trial participants in zambia In: Microbicides 2008. Delhi; 2008.
44. Mzimela AM. Understanding the impact of trial participation on condom use among women in the mdp301 clinical trial in the umkhanyakude district of northern kwazulu natal. In: Microbicides 2008. Delhi; 2008.
45. Naicker I. Strategies to limit study gel sharing between participants in microbicide development program (mdp) at medical research council (mrc) hiv prevention research unit (hpru) research sites. In: Microbicides 2008. New Delhi; 2008.
46. Nambela D. Religious affiliation and response towards clinical trials- a case for MDP Zambia. In: Microbicides 2008. New Delhi, India; 2008.
47. Namukwaya SN. Participation and knowledge among women enrolled in a phase iii microbicide trial in sw uganda In: Microbicides 2008. Delhi; 2008.
48. Nanoo A. Factors associated with adherence to study product in the mdp301 phase iii trial of pro2000/5 in johannesburg In: Microbicides 2008. New Delhi; 2008.
49. Ndlovu H, Gafos M, Newell M. Prevalence of STIs and assessment of validity of syndromic management diagnosis and treatment of STIs when compared to laboratory diagnosis in HIV uninfected women aged 18 years and over, enrolled in the MDP301 clinical trial in the Umkhanyakude District of northern KwaZulu Natal. In: XVIIth International AIDS Conference. Mexico; 2008.
50. Nyambe MP. Views on genital examination among participants in the mdp 301 trail in mazabuka zambia In: Microbicides 2008. Delhi; 2008.
51. Nyambuka SR, Shagi C, Barberousse C, et al. Addressing high pregnancy rate in a Vaginal Microbicide trial in TANZANIA. In: ICASA 2008. Dakar; 2008.
52. Phillip JL. Impact of disclosure of gel and trial participation to male partners on gel adherence among women in the microbicide development programme (mdp) 301 phase iii trial In: Microbicides 2008. Delhi; 2008.
53. Pillay S. Eligibility of women participating in trial preparedness studies for future phase iii hiv prevention trial – experience from mdp 301 phase iii trial. In: Microbicides 2008. New Dehli, India; 2008.
54. Pool R. Increasing the accuracy of adherence data in the Microbicides development programme 301 trial. In: Microbicides 2008. New Delhi; 2008.
55. Reddy K. A comparison of bacterial vaginosis (bv) testing using amsel's criteria and gram stain analysis In: Microbicides 2008. Delhi; 2008.
56. Seoka SP. Cleansing, curing and exciting: unanticipated attributes of a microbicide gel in the mdp trial, south africa In: Microbicides 2008. Delhi; 2008.
57. Shagi CN. Mobilisation with microbicide trial participants after completion to improve community In: Microbicides 2008. Dehli; 2008.
58. Sinyama P. Assessing contraceptive choice among women in the MDP 301 Trial – A Zambian Case Study. In: Microbicides 2008. Delhi; 2008.
59. Soteli S, Yona C, Moffat C, et al. The role of the community Liaison System In encouraging HIV VCT among women recruited for the MDP301 Vaginal Microbicide Trial: in Tanzania. In: ICASA 2008. Dakar; 2008.
60. Ssali AN. Pregnancy among women enrolled in a microbicide effectiveness trial of the microbicide development programme (mdp) in sw uganda In: Microbicides 2008. Delhi; 2008.
61. Terris-Prestholt F. The impact of different hiv prevention efficacies on south african women's demand for microbicides In: Microbicides 2008. Delhi; 2008.
62. Terris-Prestholt F. Facilitating microbicide use in south africa: using women's preferences to design distribution strategies In: Microbicides 2008. Delhi; 2008.
63. Walaza S. Factors associated with pregnancy in women taking part in MDP 301 phase III clinical trial in Johannesburg. In: Microbicides 2008. New Delhi, India; 2008.
64. Yona C, Ndallo M, Moffat C, et al. Exploring Empowerment of women through Trial Participation. In: ICASA 2008. Dakar; 2008.
65. Allen CF, Desmond N, Chiduo B, et al. Cleanliness, sexuality and microbicides: vaginal hygiene and vaginal substance use in the feasibility study for the MDP microbicides trial in Mwanza, Tanzania. In: ISSTDR. Seattle; 2007.
66. Arjun J, Moyes J, Walaza S, Nanoo A. A comparison of gel use at Soweto and Orange Farm sites participating in a Phase III randomized controlled trial of PRO 2000/5. In: 3rd South African AIDS Conference. Durban 2007.
67. Asmal H, Singh D, Ramjee G. Prevalence of anaemia in women screening for participation in an HIV prevention trial and the follow-up : a public health benefit. In: 3rd South African AIDS Conference. Durban; 2007.
68. Asmal H, Govender S, Naicker I, Singh D, Ramjee G. Reasons For Lack Of Contraceptive Use Amongst Women Screening for an HIV Prevention Trial and Strategies to Improve Uptake. In: 3rd South African AIDS Conference. Durban; 2007.
69. Francis SC, Allen CF, Vallely A, et al. Intra-vaginal practices in a microbicide feasibility study in Mwanza, Tanzania: Baseline associations with STI and HIV. In: ISSTDR. Seattle; 2007.
70. Gafos M, McGrath N. Comparison of sexual behaviour data collection methods used to collect data on sexual activity and sexual partnerships during a Microbicide Feasibility Study in rural KwaZulu Natal. In: 3rd South African AIDS Conference. Durban; 2007.
71. Lees S, Desmond N, Chiduo B, et al. HIV risk perceptions among women participating in a microbicide feasibility study in Mwanza, Tanzania: implications for future uptake of vaginal microbicides. In: 4th IAS Conference Sydney; 2007.
72. Mntambo A, Stadler J. Sexual preferences and the acceptability of PRO 2000/5 microbicide gel, during a phase III trial, in Johannesburg. In: 3rd South African AIDS Conference. Durban; 2007.
73. Mzimela M, Gafos M, Ndlovu H. Case Studies of themes and terms used to describe the use of a microbicide gel amongst women and their partners in rural KwaZulu Natal: Preliminary findings from qualitative interviews. In; 2007.
74. Shagi C, Vallely A, Kasindi S, et al. A model for community representation and participation in HIV prevention trials among women who engage in transactional sex in Africa. In: 4th IAS Conference. Sydney; 2007.
75. Stadler J, Seoka S, Mntambo M. Rumors about reimbursements in the MDP 301 microbicide trial in Johannesburg, South Africa. In: 3rd South African AIDS Conference; 2007.
76. Stadler J, Seoka S, Mntambo M. Rumours about reimbursements in the MDP 301 microbicide trial in Johannesburg, South Africa. In: 3rd South African AIDS Conference. Durban; 2007.
77. Subramanian L, McGrath N, Ndlovu H, Gafos M. Family planning methods among women in a vaginal microbicide feasibility study in rural KwaZulu Natal, South Africa. In: 3rd South African AIDS Conference. Durban; 2007.
78. Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C. Estimation of women’s willingness to pay (WTP) for barrier methods for HIV prevention in South Africa using OLS, Tobit, and Interval regression: comparing determinants of WTP for the female condom, diaphragm, microbicides. In; 2007.
79. Vallely A, Shagi C, Lees S, et al. Achieving equity and social justice in HIV prevention trials in developing countries: Engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania. In: 4th IAS Conference. Sidney; 2007.
80. Vallely A, Lees S, Shagi C, et al. How informed is consent? Using a continuous consent process among high-risk women who engage in transactional sex in the MDP301 vaginal microbicide trial, Mwanza, Tanzania. In; 2007.
81. Walaza S, Moyes J, Nanoo A, Arjun J, Rees H. Predictors of Pregnancy In A Phase III Microbicide Trial of PRO2000/5 In: 3rd South African AIDS Conference. Durban; 2007.
82. Allen CF, Lees SS, Desmond N, et al. Impact of level of researcher support on coital diary results and acceptability among women at high risk of HIV in the microbicides development programme feasibility study in Mwanza, Tanzania In: XVIth International AIDS Conference. Toronto; 2006.
83. Allen C, Lees S, Desmond N, et al. Validity of coital diaries in the Microbicides Development Programme feasibility study among women at high risk of HIV in Mwanza, Tanzania In: Microbicides 2006. Cape Town; 2006.
84. Arjun J, Walaza S, Moyes J, Govuzela M, Nanoo A, Rees H. An assessment of participant acceptability of a placebo gel; and its implications for use of a vaginal PRO 2000/5 gel. In: Microbicides 2006. Cape Town; 2006.
85. Bakobaki J, Rutterford C, Kaganson N, et al. A comparison of retention figures in Microbicides Development Programme feasibility and pilot studies: before and after introduction of a study product. In: Microbicides 2006. Cape Town; 2006.
86. Basajja V, Wandiembe S, Ssali A, et al. Evaluation of activities to achieve good community awareness of and participation in microbicide studies in SW Uganda. In: Microbicides 2006. Cape Town; 2006.
87. Chilatu M, Siziya S, Chisembele M, Kasonde R, Sakala O, Siyamusantu W. Condom use among the study population in the MDP pilot study Mazabuka, Zambia. In: Microbicides 2006. Cape Town; 2006.
88. Cummins J, Richardson-Harman N, Bremer J, et al. A Multi-Center evaluation of tissue explant models used for pre-clinical assessment of topical microbicides. In: Microbicides 2006. Cape Town 2006.
89. Delany S, Moyes J, Pascoe S, Readhead A, Rees H. Sexually transmitted infections may play an important role in mediating the effect of microbicides in Phase III trials. In: Microbicides 2006. Cape Town; 2006.
90. Fairhurst D, Perumal D, Cosgrove T, et al. Variability in the structure-function characteristics of polystyrene sulphonate macromolecules Impinges on the efficacy of in-vitro HIV-1 Inhibition. In: Microbicides 2006. Cape Town; 2006.
91. Gafos M, Mzimela M. Acceptability of using a vaginal gel before sex in Umkanyakude District of KwaZulu Natal. In: Microbicides 2006. Cape Town; 2006.
92. Gappoo S, Naidoo S, Ramjee G, Guddera V, Raju E. HSV2 prevalence amongst women participating in HIV prevention studies in rural communities in Durban, South Africa -Urgent need for microbicide product to be active against HSV2. In: Microbicides 2006. Cape Town; 2006.
93. Hagwamuna K, Siziya S, Chisembele M, Kasonde R. On-site HIV rapid testing experiences. In: Microbicides 2006. Cape Town; 2006.
94. Harman S, Fletcher P, Shattock R, Boothe A, Doncel G. Preclinical evaluation of lime juice as a potential microbicide. In: Microbicides 2006. Cape Town; 2006.
95. Hayes M, Hu Q, Shattock R. OA2 CpG B and C effectively inhibit R5 HIV-1 infection of cervicovaginal tissue. In: Microbicides 2006. Cape Town; 2006.
96. Hu Q, Mahmood N, Shattock R. HIV-1 Escape from cyanovirin? CN selectively depletes multiple mannose residues on gp120. In: Microbicides 2006. Cape Town; 2006.
97. Jentsch U, Hughes P, Everett D, et al. Building Laboratory Capacity in Africa: from Pilot study to Phase 3 MDP 301. In: Microbicides 2006. Cape Town; 2006.
98. Jentsch U, Hughes P, Everett D, et al. Piloting shipping of sample from MDP study sites to the central laboratory In: Microbicides 2006. Cape Town; 2006.
99. Kaganson N, Moodley J, Arjun J, Rauchenberger M. Gel returns during phase III trials. In: Microbicides 2006. Cape Town; 2006.
100. Kasse MJ, Wandiembe S, Ssali A, McCormack S, Grosskurth H, Kamali A. Acceptability and adherence to microbicide gel use instructions among couples participating in a pilot study for a phase III microbicide trial in rural SW Uganda. In: Microbicides 2006. Cape Town; 2006.
101. Lederman M, Offord R, Mosier D, et al. LB005 Targeting CCR5 as a rational and promising microbicide strategy
In: Microbicides 2006. Cape Town; 2006.
102. Lederman M, Offord R, Veazey R, et al. CCR5 sequestration by RANTES analogues: a rational and plausible strategy for topical prevention of HIV infection. In: Microbicides 2006 Cape Town; 2006.
103. Lees S, Vallely A, Cook C, et al. Comparison of sexual behaviour data collected from a coital diary and a clinic based interview in the microbicides development programme (MDP) pilot study, Mwanza, Tanzania In: XVIth International AIDS Conference. Toronto; 2006.
104. Liu S, Lu H, Wallace G, Hu Q, Shattock R, Jiang S. An entry inhibitor targeting gp41, prevents HIV-1 transmission in the in vitro and ex vivo models. In: Microbicides 2006. Cape Town; 2006.
105. Lunga P, Montgomery C, McCormack S, Ssali A, Pool R. Informed consent and participant understanding of trial procedures in a phase III pilot study. In: Microbicides 2006. Cape Town; 2006.
106. MacPhail C, Terris-Prestholt F, Kumaranayake L, Ngoako P, Rees H, Watts C. Managing male partners: women's dilemmas about overt & covert use of new barrier methods for HIV prevention. In: Microbicides 2006. Cape Town 2006.
107. Margolis L, Shattock R. Selective transmission of CCR5-Utilizing HIV-1: “The Gatekeeper” problem resolved? In: Microbicides 2006. Cape Town; 2006.
108. Mawyi E, Delany S, Moyes J, Watts C. Do we need secondary HIV prevention in microbicide trials? In: Microbicides 2006. Cape Town; 2006.
109. McCormack S, Moyes J, Walaza S, et al. The challenge of collecting, collating and reporting adverse event data in microbicide trials. In: Microbicides 2006. Cape Town; 2006.
110. Mncwango N, Mcoyi C, Mthembu S, Gafos M. “Roadshows” as a community engagement strategy for microbicide research in rural South Africa. In: Microbicides 2006. Cape Town; 2006.
111. Mnguni GB, Msimang N, Nkosi N, Gafos M. Using proactive participant retention techniques in the Microbicides Development Programme (MDP) pilot study at the Africa Centre in the Umkhanyakude District of KwaZulu Natal, South Africa. In: Microbicides 2006. Cape Town; 2006.
112. Mntambo M, Stadler J, Delany S, Moyes J, Tamm N. Community mobilization for research: Using community radio to create awareness of microbicide research in Soweto, South Africa. In: Microbicides 2006. Cape Town; 2006.
113. Mollendorf CV, Moyes J, Rees H. The challenges of recruitment and enrolment into a safety and acceptability study of the diaphragm and ACIDFORM gel or placebo. In: Microbicides 2006. Cape Town; 2006.
114. Montgomery C, Gafos M, Lees S, et al. Partner Communication and decision-making in a phase III pilot microbicide study. In: Microbicides 2006. Cape Town; 2006.
115. Moyes J, Delany S, Rees H. Testing for HIV: Field performance of two rapid tests in a South African population. In: Microbicides 2006. Cape Town; 2006.
116. Moyes J, Delany S, Stadler J, et al. Developing a community entry strategy: preparing for a phase III microbicide trial. In: Microbicides 2006. Cape Town; 2006.
117. Mundia K, Siziya S, Chisembele M, et al. Discussing the standardization of Community Adivisory Groups (CAGs) memorandum of understanding (MOU) across MDP sites: experience from the MDP Zambian site. In: Microbicides 2006. Cape Town; 2006.
118. Musonda M, Siziya S, Chisembele M, Kasonde R, Siyamusantu W, Sakala O. Acceptability of CD among participants during pilot phase at MDP Zambia. In: Microbicides 2006. Cape Town; 2006.
119. Mutemwa R, Morar N, Stones W, et al. Challenges in collating community involvement experiences from sites in Africa preparing for the Microbicides Development Programme (MDP) multi-centre Phase III clinical trial. In: Microbicides 2006. Cape Town; 2006.
120. Mutevedzi P, Ndlovu H, Jentsch U. Piloting biological sample testing and tracking for the microbicides development programme (MDP) 301 study in umkhanyakunde district, kwazulu natal, South Africa. In: Microbicides 2006. Cape Town; 2006.
121. Mwanza B, Siziya S, Chisembele M, Kasonde R, Siyamusantu W, Sakala O. Dry sex and the acceptability of microbicides gel. In: Microbicides 2006. Cape Town; 2006.
122. Mwanza B, Siziya S, Chisembele M, Kasonde R, Siyamusantu W, Sakala O. Vaginal washing: a threat in evaluating microbicides effectiveness. In: Microbicides 2006. Cape Town; 2006.
123. Mzimela M, Gafos M. Measuring and assessing variability in self-reported sexual behavior data collected using different methods during the microbicides development programme pilot study at the Africa centre for health and population studies in the Umkhanyakude district of Kw. In: Microbicides 2006. Cape Town; 2006.
124. Naidoo K, Dorsamy E, Naidoo B, et al. Preventing co-enrolment in multiple clinical trials in Durban, South Africa. In: Microbicides 2006. Cape Town; 2006.
125. Namutebi AM, Wandiembe S, Bukenya A, McCormack S, Grosskurth H, Kamali A. Enabling access to contraception among women participating in a vaginal microbicide efficacy trial in rural SW Uganda. In: Microbicides 2006. Cape Town; 2006.
126. Ndlovu H, McGrath N. Self-reported symptoms of Sexually Transmitted Infections and treatment-seeking behaviour in the Microbicides Development Programme (MDP) feasibility study at the Africa Centre, Umkhanyakude district, KwaZulu Natal, South Africa. In: Microbicides 2006. Cape Town; 2006.
127. Nene N, Veerasami S, Naidu N, Morar NS, Ramjee G. Undiagnosed genital infections among women participating in an MDP Pilot study as a result of lack of acknowledgement of abnormal symptoms. In: Microbicides 2006. Cape Town; 2006.
128. Nene N, Guddera V, Morar N, Ramjee G. Pilot study to predict estimated screening sample size for phase III microbicide trial. In: Microbicides 2006. Cape Town; 2006.
129. Nunn A, Rutterford C, Hayes R, McCormack S. Proving efficacy in microbicide trials: What design, how many women and for how long? In: Microbicides 2006. Cape Town; 2006.
130. Perumal D, Gwozdz G, Goldman L, et al. Novel TMC120 gel formulation demonstrates potent anti-HIV-1 activity in cellular and human cervical tissue models. In: Microbicides 2006. Cape Town; 2006.
131. Phillip L, Morar NS, Ramjee G. Disclosure of microbicide use to male partners: impact on gel adherence and trial participation among couples in a HIV prevention trial. In: Microbicides 2006. Cape Town; 2006.
132. Phillip JL, Morar N, Pool R, Ramjee G. The acceptability of a placebo gel in preparation for the microbicides development programme phase III trial in Durban, South Africa. In: Microbicides 2006. Cape Town; 2006.
133. Phillip JL, Morar N, Ramjee G. Assessment of informed consent in the microbicide development programme feasibility study Durban, South Africa. In: Microbicides 2006. Cape Town; 2006.
134. Pool R, Ssali A, Mnambo M, et al. Local translations of sexual behaviour terms - impact on data validity in HIV Prevention research. In: Microbicides 2006. Cape Town; 2006.
135. Pool R. Innovative uses of multi-method triangulation to increase the accuracy of adherence and sexual behaviour data in the MDP301 trial. In: Microbicides 2006. Cape Town; 2006.
136. Rutterford C, Nunn A, Wandiembe SP. Assessment of adherence to gel and condom use in the microbicides development programme pilot study. In: Microbicides 2006. Cape Town; 2006.
137. Saethre E, Stadler J. Culture, AIDS and Africa: HIV/AIDS narratives in Orange Farm, Gauteng. In: ASnA, PAAA, IUAES Conference. Cape Town; 2006.
138. Sexton A, Shattock R, Ma J. Transgenic plant production of Cyanovirin-N, an HIV microbicide. In: Microbicides 2006. Cape Town; 2006.
139. Shattock R. Protection of macaques against rectal SIV challenge by mucosally-applied PMPA. In: Microbicides 2006. Cape Town; 2006.
140. Sinyama P, Siziya S, Chisembele M, Kasonde R, Siyamusantu W. Assess factors affecting the understanding of the informed consent forms in the pilot phase - A zambian case. In: Microbicides 2006. Cape Town; 2006.
141. Sitali C, Siziya S, Chisembele M, Kasonde R. Recruitment and reasons for drop-out on feasibility study - Zambia. In: Microbicides 2006. Cape Town; 2006.
142. Siziya S. Acceptability of VCT among persons living in a high HIV prevalence area in Zambia. In: Microbicides 2006. Cape Town; 2006.
143. Ssali AS. Acceptability of gel and condom use and of STI partner notification among couples preparing for a microbicide development programme effectiveness trial In: XVIth International AIDS Conference. Toronto; 2006.
144. Ssali A, Lubega R, Nalukenge W, et al. Evaluation of informed consent procedures and reasons for participation in a pilot study for a vaginal microbicide trial among women in SW Uganda. In: Microbicides 2006. Cape Town; 2006.
145. Stadler J, Dugmore C, Mntambo M, Kubeka V. Cognitive mapping as a strategy for community entry in a clinical trial: the case of Orange Farm. In: Microbicides 2006. Cape Town; 2006.
146. Stadler J, Mntambo M, Qwana E, Delany S, Moyes J, Rees H. The social context and impact of a clinical trial: results from a feasibility study in Soweto, South Africa. In: Microbicides 2006. Cape Town; 2006.
147. Stefanidou M, Martinez O, Hayes M, et al. Evaluation of gold manno-nanoparticles in a model for DC-SIGN binding and dissemination of HIV-1. In: Microbicides 2006. Cape Town; 2006.
148. Subramanian L, Mzimela M, Gafos M. Frequency of sex acts and condom use in a Microbicides Development Programme
Pilot Study in South Africa. In: Microbicides 2006. Cape Town; 2006.
149. Terris-prestholt F, Kumaranayake L, Macphail C, Rees H, Watts C. Distributing barrier methods for women: determinants of willingness to pay for microbicides, the diaphragm and the female condom. In: XVIth International AIDS Conference. Toronto; 2006.
150. Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C. Determinants of willingness to pay for barrier methods: microbicides, diaphragm and female condom. In: Microbicides 2006. Cape Town; 2006.
151. Terris-Prestholt F, Kumaranayake L, MacPhail C, et al. Preferences for female barrier methods and their distribution: what South African women want. In: Microbicides 2006. Cape Town; 2006.
152. Vallely A, Hambleton I, Kasindi S, et al. Microbicides development programme, Tanzania. Are high-risk women who work in bars, guesthouses and similar facilities a suitable study population for clinical trials of vaginal microbicides in Africa? In: Microbicides 2006. Cape Town; 2006.
153. Vallely A, Kasindi S, Changalucha J, et al. Are high-risk women who work in bars, guesthouses and similar facilities a suitable study population for phase III clinical trials of vaginal microbicides in Africa? In: Microbicides 2006. Cape Town; 2006.
154. Wallace G, Schito M, Appella E, Shattock R. HIV-1 nucleocapsid zinc finger inhibitors (zfi’s) impede HIV-1 trans infection in cellular and explant models. In: Microbicides 2006. Cape Town; 2006.
155. Wandera N, Lees S, Wayomi J, et al. Microbicides development programme: placebo vaginal gel acceptability amongst women at high-risk of HIV in Mwanza, Tanzania In: XVIth International AIDS Conference. Toronto; 2006.
156. Wandiembe SP, Ssali A, Basajja V, McCormack S, Grosskurth H, Kamali A. Potential barriers to adherence to product use and cohort retention in microbicides efficacy trials. In: Microbicides 2006. Cape Town; 2006.
157. Wandiembe S, Ssali A, McCormack S, Kamali A, Grosskurth H. Towards HIV prevention method for women: Preparation of Vaginal Microbicide Safety and Efficacy Trials in Africa. In: MRC Infections and Immunity Showcase; 2006.
158. Arjun J, Moyes J, Walaza S, et al. A pilot study in preparation for a randomised control trial of a vaginal microbicide: an assessment of participant understanding of gel dispensing instructions and a comparison of the methods for data collection. In: 2nd South African AIDS Conference. Durban; 2005.
159. Kasse KM. Acceptability of genital examinations and estimation of STI prevalence among women participating in a microbicides feasibility study in rural SW Uganda In: XVIth International AIDS Conference. Toronto; 2005.
160. Lees S, Allen C, Desmond N, et al. Can Coital Diaries Provide Reliable Data on Sexual Behaviours in Mwanza, Tanzania? . In: ISSTDR. Amsterdam; 2005.
161. Lees S, Desmond N, Shagi C, Vallely A, Allen C, Ross D. Body and Personhood: Addressing rumours in vaginal microbicide medical research in Mwanza, Tanzania as part of the Microbicides Development Programme. In: Conference on the Ethnography of Medical Research. Kenya; 2005.
162. Moyes J, Delany-Moretlwe S, Rees H. Field performance of HIV rapid testing in a female population in Johannesburg. In: 2nd South African AIDS Conference. Durban; 2005.
163. Ngcobo MS, Rapiti R, Ramjee G. Challenges of performing regular clinical speculum examinations in HIV prevention clinical trials among women. In: 2nd South African AIDS Conference. Durban; 2005.
164. Ouma J, Nalukenge W, Lubega R, et al. Acceptability of gel and condom use and of STI partner notification among couples preparing for a microbicide development programme effectiveness trial. In. Amsterdam; 2005.
165. Phillip JL, Morar NS, Ramjee G. Assessment of Informed Consent in a Microbicide Feasibility Study. In: 2nd South African AIDS Conference. Durban; 2005.
166. Raju E, Ramkylas B, Ngcobo S, Nunn A, McCormack S, Ramjee G. Prevalence of HIV and co-infection with HSV2 among women in the communities of Tongaat and Verulam, Durban, South Africa. In: 2nd South African AIDS Conference. Durban; 2005.
167. Raju E, Naiker S, Rapiti R, et al. Site feasibility study to assess prevalence and incidence of HIV in preparation for Microbicide Development Programme's Phase III clinical trial site in Durban, South Africa. In: 2nd South African AIDS Conference. Durban; 2005.
168. Rapiti R, Morris N, Ramjee G. Use of Geographical Positioning Systems (GPS) as a tool to determine HIV prevalence and incidence areas in communities - a novel approach for targeted interventions. In: 2nd South African AIDS Conference. Durban; 2005.
169. Ssali A, Ouma J, Nalukenge W, et al. Male involvement and partner notification among couples in a microbicide feasibility study in SW Uganda. In. Amsterdam; 2005.
170. Vallely A, Kasindi S, Knight L, et al. Characteristics of the Mwanza occupational cohort at baseline and factors associated with re-attendance at three months. In. Amsterdam; 2005.
171. Allen C, Desmond N, Hayes R, et al. Coital diaries to measure frequency of sexual practices in mwanza, tanzania In: Microbicides 2004. London; 2004.
172. Annie M, Bhat G, Siziya S, et al. The assesment of different methods of collecting sexual information data on condom use. In: Microbicides 2004. London; 2004.
173. Delany S, Fakude G, Metsileng D, Nkala B, Moyes J, Rees H. Is hiv testing in hiv prevention trials acceptable? Results from a study in soweto In: Microbicides 2004. London; 2004.
174. Desai K, Garnett GP. How reliable does self-reported sex behaviour need to be for valid microbicide efficacy estimation? . In: Microbicides 2004. London; 2004.
175. Desmond N, Allen C, Chiduo B, et al. Sexual practices of women recruited to a microbicide trial feasibility study in mwanza,tanzania In: Microbicides 2004. London; 2004.
176. Kasse M, Ssali A, Pickering J, Kamali A, Grosskurth H. Vaginal hygiene and use of intravaginal products among women in rural sw uganda In: Microbicides 2004. London; 2004.
177. Kubeka V, Moyes J, Stadler J, et al. The process of forming a community advisory group: experiences from a feasibility study in soweto In: Microbicides 2004. London; 2004.
178. Magadi M, Madise N. Behavioural challenges to microbicide gel acceptance and use in sub-saharan africa In: Microbicides 2004. London; 2004.
179. Mc Cormack S, Kaganson N, Hayes R, Nunn A. Reaching consensus: developing an agreed clinical trial protocol for a multi-centre microbicide rct In: Microbicides 2004. London; 2004.
180. McGrath N, Hosegood V. Disclosure of study participation and hiv status among women in a microbicide feasibility study In: Microbicides 2004. London; 2004.
181. Mutemwa R, Basajja V, Shagi C, et al. Mobilising community involvement in randomised microbicide clinical trials: lessons from 6 mdp sites In: Microbicides 2004. London; 2004.
182. Mweemba O, Bhat G, Mshanga A, et al. Dry sex practice in a zambian community In: Microbicides 2004. London; 2004.
183. Naiker S, Nair G, Ramjee G. Do site feasibility studies contribute to the planning of phase iii microbicide trials? . In: Microbicides 2004. London; 2004.
184. Ndinda C, Chimbwete C, McGrath N. The prevalence of anal sex in rural south africa In: Microbicides 2004. London; 2004.
185. Ndinda C, McGrath N. Community attitudes towards individuals infected with hiv in rural kwa-zulu natal In: Microbicides 2004. London; 2004.
186. Ouma J, Pickering J, Kamali A, Grosskurth H. Intentions to become pregnant: data from a feasibility study for a phase iii microbicide trial In: Microbicides 2004. London; 2004.
187. Paul N, Morris N, Morar N, Ramjee G. Situational analysis of hiv related standard of care available among targeted research communities In: Microbicides 2004. London; 2004.
188. Qwana E, Stadler J, Nkungwana S. Anal sex and condom use amongst participants in a microbicide feasibility study In: Microbicides 2004. London; 2004.
189. Sangeeta S, Cowen M, Kaganson N, et al. An open phase 1 trial of 13% cellulose acetate phthalate (cap) vaginal microbicide. . In: Microbicides 2004. London; 2004.
190. Sangeeta S, Cowen M, Conder G, et al. Magnetic resonance imaging study of the distribution and retention of dextrin sulphate In: Microbicides 2004. London; 2004.
191. Sangeeta S, Holmes A, Richardson D, et al. Vaginal hygeine practices in a london, uk population In: Microbicides 2004. London; 2004.
192. Ssali A, Kasse M, Bassajja V, Pickering J, Kamali A, Grosskurth H. Sexual behaviour and attitudes towards vaginal microbicides among couples in rural sw uganda In: Microbicides 2004. London; 2004.
193. Terris-Prestholt F, Nowitz D, Kumaranayake L, et al. Launching microbicides,how important is promotion? Lessons from condom social marketing In: Microbicides 2004. London; 2004.
194. Twefeho B, Jjuko D, Kironde N. Couple hiv counselling and testing in feasibility study for a phase iii microbicide trial in uganda In: Microbicides 2004. London; 2004.
195. Vallely A, Changalucha J, Gavyole A, Ross D, Watson-Jones D, Hayes R. Microbicide trial feasibility study in high-risk women in mwanza, tanzania: lessons learned In: Microbicides 2004. London; 2004.
|
